Trial: 202103232

A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC # 748726, IND#125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged > 1 to < 31 Years Old with First Relapse



Principal Investigator

Hayashi, Robert

Disease Site

Lymphoid Leukemia

Learn more about this study at: